<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Modeling and Simulation을 이용한 Special population에서의 약물 인허가 현황과 관련규정</title>
  <meta name="description" content="Modeling and Simulation을 이용한 Special population에서의 약물 인허가 현황과 관련규정">
  <meta name="generator" content="bookdown 0.5.9 and GitBook 2.6.7">

  <meta property="og:title" content="Modeling and Simulation을 이용한 Special population에서의 약물 인허가 현황과 관련규정" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Modeling and Simulation을 이용한 Special population에서의 약물 인허가 현황과 관련규정" />
  
  
  

<meta name="author" content="Sungpil Han">


<meta name="date" content="2017-11-16">

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="index.html">
<link rel="next" href="regulation.html">
<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css\style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> 서론</a></li>
<li class="chapter" data-level="2" data-path="approval.html"><a href="approval.html"><i class="fa fa-check"></i><b>2</b> 모델링과 시뮬레이션을 이용한 특수집단에서 약물 인허가 현황</a><ul>
<li class="chapter" data-level="2.1" data-path="approval.html"><a href="approval.html#-fda---"><i class="fa fa-check"></i><b>2.1</b> 미국 FDA의 인허가에 사용된 예</a></li>
<li class="chapter" data-level="2.2" data-path="approval.html"><a href="approval.html#-emea---"><i class="fa fa-check"></i><b>2.2</b> 유럽 EMEA의 인허가에서 사용된 예</a></li>
<li class="chapter" data-level="2.3" data-path="approval.html"><a href="approval.html#-pmda---"><i class="fa fa-check"></i><b>2.3</b> 일본 PMDA의 인허가에서 사용된 예</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="regulation.html"><a href="regulation.html"><i class="fa fa-check"></i><b>3</b> 모델링과 시뮬레이션 관련 규정</a><ul>
<li class="chapter" data-level="3.1" data-path="regulation.html"><a href="regulation.html#fda"><i class="fa fa-check"></i><b>3.1</b> FDA</a></li>
<li class="chapter" data-level="3.2" data-path="regulation.html"><a href="regulation.html#emea"><i class="fa fa-check"></i><b>3.2</b> EMEA</a></li>
<li class="chapter" data-level="3.3" data-path="regulation.html"><a href="regulation.html#pmda"><i class="fa fa-check"></i><b>3.3</b> PMDA</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="ecb0b8eab3a0ebacb8ed978c.html"><a href="ecb0b8eab3a0ebacb8ed978c.html"><i class="fa fa-check"></i>참고문헌</a></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Modeling and Simulation을 이용한 Special population에서의 약물 인허가 현황과 관련규정</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="approval" class="section level1">
<h1><span class="header-section-number">2</span> 모델링과 시뮬레이션을 이용한 특수집단에서 약물 인허가 현황</h1>
<div id="-fda---" class="section level2">
<h2><span class="header-section-number">2.1</span> 미국 FDA의 인허가에 사용된 예</h2>
<p>180건의 PBPK 모델링이 접수되었다. <span class="citation">(Mehrotra et al. <a href="#ref-Mehrotra_2016">2016</a>)</span></p>
<!--Based on the PBPK review knowledgebase of the Office of Clinical Pharmacology, there are 180 records between 2008 and 2015 addressing various clinical pharmacology issues. Sixty-six percent of these records fall into the category of predicting drug-drug interaction potential, with the remaining 34% equally distributed between pediatric PK prediction and other applications (e.g., drug absorption, pharmacogenetics, and organ impairment) (Fig. 5). Of the 31 pediatric review records, distribution of therapeutic areas is shown in Fig. 5. Based on the regulatory experience, compared with drug-drug interaction prediction, the confidence in prospectively using PBPK predictions to recommend pediatric dosing regimen is lower. The lower confidence in using PBPK to predict drug PK in pediatrics is mainly attributed to uncertainty and knowledge gaps in developmental changes governing absorption, distribution, metabolism, and excretion processes mediated by metabolizing enzymes, binding proteins, and transporters. Therefore, one anticipates the system model for the pediatric population of a specific age group to be updated when new information becomes available. Salem and colleagues (2014) recently used clinical PK data for CYP3A substrates to derive and update the ontogeny profile for the enzyme. At the present time, the use of PBPK in regulatory submissions focuses on optimizing the study design of pediatric PK studies with the goal of maximizing the utility of knowledge gained from these studies upon completion. The regulatory review experiences and understanding of the state of science led to the conclusion that there is a lack of established predictive performance of PBPK in the area of pediatric PK prediction (Wagner et al., 2015).-->
<p>FDA의 특수 환자에 대한 약물 허가에서 예가 제시 되었다. (표 <a href="approval.html#tab:fda-list">2.1</a>) 여러가지 예가 제시되었지만 소아에서 에소메프라졸을 미란성 식도염을 동반한 GERD 치료시 정맥 투여 용법을 예측하는데 사용한 예를 대표적으로 들 수 있다. <span class="citation">(Mehrotra et al. <a href="#ref-Mehrotra_2016">2016</a>)</span> 소아용 약물의 개발에서 생리기반 약동학 모델링으로 약물을 평가하여 인허가를 결정하는 다수의 예가 보고되고 있다. <span class="citation">(Leong et al. <a href="#ref-Leong_2012">2012</a>; Mehrotra et al. <a href="#ref-Mehrotra_2016">2016</a>)</span></p>
<p>CYP450 효소와 발달 과정의 여러 생리학적 인자를 수치화 하여 PBPK 모델링으로 용량-반응 관계를 평가가능하다. <span class="citation">(Leong et al. <a href="#ref-Leong_2012">2012</a>)</span> 네가지 약물에 대해서 각 특성을 정리하였다.</p>
<p>FDA에서 모델링과 시뮬레이션을 활용한 약물의 허가 사항에서 레이블에 반영되는 예는 증가 추세에 있으며 심사에서 사용되는 경우는 더 많아서 2015년 40개에 이른다. (그림 <a href="approval.html#fig:drug-label">2.1</a>) <span class="citation">(Zhao <a href="#ref-drug-label">2016</a>)</span></p>
<!--Mehrotra의 서론 부분을 요약.-->
<table>
<caption><span id="tab:fda-list">Table 2.1: </span>FDA의 특수 환자에 대한 약물 허가에서 예</caption>
<thead>
<tr class="header">
<th align="left">구분</th>
<th align="left">약물</th>
<th align="left">출처</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left">소아</td>
<td align="left">Esomeprazole</td>
<td align="left">Mehrotra <em>et al</em>, 2016</td>
</tr>
<tr class="even">
<td align="left">소아</td>
<td align="left">Vigabatrin</td>
<td align="left">Mehrotra <em>et al</em>, 2016</td>
</tr>
<tr class="odd">
<td align="left">소아</td>
<td align="left">Adalimumab</td>
<td align="left">Mehrotra <em>et al</em>, 2016</td>
</tr>
<tr class="even">
<td align="left">소아</td>
<td align="left">Darunavir</td>
<td align="left">Mehrotra <em>et al</em>, 2016</td>
</tr>
<tr class="odd">
<td align="left">소아</td>
<td align="left">Topiramate</td>
<td align="left">NA</td>
</tr>
<tr class="even">
<td align="left">소아</td>
<td align="left">Pralidoxime</td>
<td align="left">NA</td>
</tr>
<tr class="odd">
<td align="left">소아</td>
<td align="left">Peramivir</td>
<td align="left">NA</td>
</tr>
</tbody>
</table>
<ol style="list-style-type: decimal">
<li>Esomeprazole in Pediatrics for the Treatment of Gastroesophageal Reflux Disease with Erosive Esophagitis: Intravenous Dose Selection <span class="citation">(Mehrotra et al. <a href="#ref-Mehrotra_2016">2016</a>)</span></li>
<li>Approval of Vigabatrin for Refractory Complex Partial Seizures in Pediatrics (Mehrotra, 2016, Drug Metabolism and Disposition)</li>
<li>Adalimumab: Crohn’s Disease in Children: Dose Selection (Mehrotra, 2016, Drug Metabolism and Disposition)</li>
<li>Darunavir : Exposure-Response and PK Matching to Bridge Dosing for Different Patient Populations in Pediatrics for the Treatment of Human Immunodeficiency Virus (Mehrotra, 2016, Drug Metabolism and Disposition)</li>
<li>Topiramate: Topiramate Dosing Regimen was Derived by Matching Steady State Trough Concentrations (CMIN) for Different Age Groups</li>
<li>Pralidoxime: Derived and recommended Pediatric Dosing Recommendations without any empirical data</li>
<li>Peramivir: Derived and recommended Pediatric Dosing Recommendations without any empirical data</li>
</ol>
<div class="figure"><span id="fig:drug-label"></span>
<img src="assets/drug-label.jpg" alt="2009-2015년 동안 PBPK에 의한 용량 권고 사항이 약물 레이블에 반영된 예 [@drug-label]" width="800" />
<p class="caption">
Figure 2.1: 2009-2015년 동안 PBPK에 의한 용량 권고 사항이 약물 레이블에 반영된 예 <span class="citation">(Zhao <a href="#ref-drug-label">2016</a>)</span>
</p>
</div>
</div>
<div id="-emea---" class="section level2">
<h2><span class="header-section-number">2.2</span> 유럽 EMEA의 인허가에서 사용된 예</h2>
<p>2013년에 설립된 MSWG은 EMEA 내의 계량약리학과들로 구성되어 있어 모델링과 시뮬레이션에 대한 평가를 한다. 2015년 EMEA MSWG (Modeling and Simulation Working Group)에 의뢰된 관련 업무의 사례 수 (그림 <a href="approval.html#fig:mswg">2.2</a>)</p>
<p>The Modelling and Simulation Working Group (MSWG) was established in January 2013 to provide specialist scientific support to the SAWP, PDCO and CHMP in the form of feedback on technical issues around how companies propose to use modelling and simulation in support of registration dossiers. The drivers for establishing such a group came from both internal and external sources. From January 2016 to December 2016, 105 product related procedures were referred to the MSWG with 41 from PDCO, 62 from SAWP, 2 from CHMP and 7 Guidelines. A breakdown of the scope of questions addressed by M&amp;S is shown in the pie chart below: Scope of M&amp;S in regulatory submissions as experienced by MSWG</p>
<div class="figure"><span id="fig:mswg"></span>
<img src="assets/emea.png" alt="2015년 EMEA MSWG (Modeling and Simulation Working Group)에 의뢰된 관련 업무의 사례 수. Reference: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/03/WC500222778.pdf" width="800" />
<p class="caption">
Figure 2.2: 2015년 EMEA MSWG (Modeling and Simulation Working Group)에 의뢰된 관련 업무의 사례 수. Reference: <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/03/WC500222778.pdf" class="uri">http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/03/WC500222778.pdf</a>
</p>
</div>
</div>
<div id="-pmda---" class="section level2">
<h2><span class="header-section-number">2.3</span> 일본 PMDA의 인허가에서 사용된 예</h2>
<p>2016년 10월부터 일본의 PMDA는 전자 문서로 NDA를 받기 시작하였다. 이를 통하여 모델링과 시뮬레이션이 포함된 NDA에 대한 정보를 조회하는 것이 보다 용이해 졌으며 Sato 등은 이를 요약하여 논문으로 제시하였다. <span class="citation">(Sato et al. <a href="#ref-Sato_2017">2017</a>)</span> 2014년에서 2016년까지 PBPK를 사용한 17개의 NDA가 PMDA에 제출되었다. (그림 <a href="approval.html#fig:pmda">2.3</a>)</p>
<div class="figure"><span id="fig:pmda"></span>
<img src="assets/japan.jpg" alt="PBPK가 사용되어 작성된 17개 약물 NDA의 분류 [@Sato_2017]" width="800" />
<p class="caption">
Figure 2.3: PBPK가 사용되어 작성된 17개 약물 NDA의 분류 <span class="citation">(Sato et al. <a href="#ref-Sato_2017">2017</a>)</span>
</p>
</div>
<!--In Japan in October 2016, the Pharmaceuticals and Medical Devices Agency (PMDA) began to receive electronic data in new drug applications (NDAs). These electronic data are useful to conduct regulatory assessment of sponsors’ submissions and contribute to the PMDA's research. In this article, we summarize the number of submissions of quantitative modeling and simulation (M&S) documents in NDAs in Japan, and we describe our current thinking and activities about quantitative M&S in PMDA.-->
</div>
</div>
<h3>참고문헌</h3>
<div id="refs" class="references">
<div id="ref-Mehrotra_2016">
<p>Mehrotra, N., A. Bhattaram, J. C. Earp, J. Florian, K. Krudys, J. E. Lee, J. Y. Lee, et al. 2016. “Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.” <em>Drug Metabolism and Disposition</em> 44 (7). American Society for Pharmacology &amp; Experimental Therapeutics (ASPET): 924–33. doi:<a href="https://doi.org/10.1124/dmd.116.069559">10.1124/dmd.116.069559</a>.</p>
</div>
<div id="ref-Leong_2012">
<p>Leong, R, M L T Vieira, P Zhao, Y Mulugeta, C S Lee, S-M Huang, and G J Burckart. 2012. “Regulatory Experience with Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials.” <em>Clinical Pharmacology &amp; Therapeutics</em> 91 (5). Springer Nature: 926–31. doi:<a href="https://doi.org/10.1038/clpt.2012.19">10.1038/clpt.2012.19</a>.</p>
</div>
<div id="ref-drug-label">
<p>Zhao, Liang. 2016. <em>Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation; Public Workshop</em>. U.S. Department of Health; Human Services Food; Drug Administration. <a href="https://www.fda.gov/downloads/Drugs/NewsEvents/UCM505000.pdf" class="uri">https://www.fda.gov/downloads/Drugs/NewsEvents/UCM505000.pdf</a>.</p>
</div>
<div id="ref-Sato_2017">
<p>Sato, M, Y Ochiai, S Kijima, N Nagai, Y Ando, M Shikano, and Y Nomura. 2017. “Quantitative Modeling and Simulation in PMDA: A Japanese Regulatory Perspective.” <em>CPT: Pharmacometrics &amp; Systems Pharmacology</em> 6 (7). Wiley-Blackwell: 413–15. doi:<a href="https://doi.org/10.1002/psp4.12203">10.1002/psp4.12203</a>.</p>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="index.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="regulation.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"download": null,
"toc": {
"collapse": "subsection"
}
});
});
</script>

</body>

</html>
